Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04977986
Other study ID # ZYN2-CL-033
Secondary ID
Status Recruiting
Phase Phase 3
First received
Last updated
Start date September 13, 2021
Est. completion date May 2025

Study information

Verified date October 2023
Source Zynerba Pharmaceuticals, Inc.
Contact Nancy Tich, PhD
Phone 973-727-4117
Email ntich@harmonybiosciences.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a randomized, double-blind, placebo-controlled, multiple-center study, to assess the efficacy and safety of Cannabidiol administered as ZYN002 for the treatment of children, adolescent, and young adult patients with Fragile X Syndrome (FXS). Eligible participants will participate in up to an 18-week treatment period, where all participants will receive placebo or active study drug. Patients ages 3 to < 23 years will be eligible to participate.


Description:

This is a randomized, double-blind, placebo-controlled, multiple-center study, to assess the efficacy and safety of ZYN002, a pharmaceutically manufactured cannabidiol, formulated as a clear gel that can be applied to the skin (called transdermal delivery), in children, adolescents, and young adults with FXS. 204 male and female patients, ages 3 to < 23 years, will be randomized 1:1 to either trial drug or placebo and will undergo an 18-week treatment period. Randomization will be stratified by gender, methylation status and weight. The study will be comprised of a Screening visit and a combination of seven visits both onsite (face-to-face) and virtual. The assignment of study drug or placebo will be done by a computer-generated system and neither the study doctor, participant or their caregivers will know which treatment is being given to them. The dose of the treatment will depend on the weight of the participants. If the participants weigh less than or equal to 30 kg, they will receive 2 sachets of the gel per day (1 sachet approximately every 12 hours). If the participant weighs more than 30 kg but less than or equal to 50 kg, they will receive 4 sachets of gel per day (2 sachets approximately every 12 hours). Participants who weigh more than 50 kg will receive 6 sachets of gel per day (3 sachets approximately every 12 hours). Parents/ caregivers will be instructed on proper application of the gel. The gel will be applied to clean, dry, intact skin of the upper arms/ shoulders. Blood samples will be collected for safety analysis of ZYN002. An independent analytical laboratory will also perform CGG repeat and methylation status analyses. Additionally, the parents/caregivers and study doctor will be asked to complete some questionnaires for efficacy and safety assessment.


Recruitment information / eligibility

Status Recruiting
Enrollment 204
Est. completion date May 2025
Est. primary completion date May 2025
Accepts healthy volunteers No
Gender All
Age group 3 Years to 23 Years
Eligibility Inclusion Criteria: - Male or female children and adolescents aged 3 to < 23 years, at the time of Screening. - Patient resides with caregiver who will continue to provide consistent care throughout the study. - Judged by the Investigator to be in generally good health at Screening based upon the results of medical history, physical exam, 12-lead ECG and clinical laboratory test results. -Laboratory results outside the reference range must be documented as not clinically significant by both the Investigator and Sponsor. - Participants must have a diagnosis of FXS through molecular documentation of full mutation of the FMR1 gene documented through genetic testing at Screening. - Patients with a history of seizure disorders must currently be receiving treatment with a stable regimen of no more than two anti-seizure medications (ASMs) for the four weeks preceding study Screening; or must be seizure-free for one year if not currently receiving ASMs. - Patients taking psychoactive medication(s) should be on a stable regimen of not more than three such medications for at least fours weeks preceding Screening and must maintain that regimen throughout the study. Psychoactive medications include (but are not limited to) antipsychotics, antidepressants, anxiolytics, attention-deficit / hyperactivity disorder (ADHD) medications, and medications for sleep. - If patients are receiving non-pharmacological, behavioral and/or dietary interventions, they must be stable and have been doing so for three months prior to screening. - Patients have a body mass index between 12-30 kg/m2 (inclusive). - Females of childbearing potential must have a negative serum pregnancy test at the Screening Visit and a negative serum or urine pregnancy test at all designated visits. - Patients and parents/caregivers must be adequately informed of the nature and risks of the study and given written informed consent prior to Screening. - Patients and parents/caregivers agree to abide by all study restrictions and comply with all study procedures, and in the Investigator's opinion, are reliable and willing and able to comply with all protocol requirements and procedures. Exclusion Criteria: - Females who are pregnant, nursing or planning a pregnancy; females of childbearing potential and male patients with a partner of childbearing potential who are unwilling or unable to use an acceptable method of contraception as outlined below for the duration of therapy and for three months after the last dose of study medication. Standard acceptable methods of contraception include abstinence (defined as refraining from heterosexual intercourse from screening to three months after the last dose of study medication) or the use of a highly effective method of contraception, including hormonal contraception, diaphragm, cervical cap, vaginal sponge, condom, spermicide, vasectomy, or intrauterine device. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the subject. Periodic abstinence (calendar, symptothermal, post-ovulation methods) is not an acceptable method of contraception. - Patient has transitioned to independent living or living in a residential facility such as a university setting or congregate care. - History of significant allergic condition, significant drug-related hypersensitivity, or allergic reaction to any compound or chemical class related to ZYN002 or its excipients. - Exposure to any investigational drug or device less than or equal to 30 days prior to Screening or at any time during the study. - Alanine aminotransferase (ALT), aspartate aminotransferase (AST) or total bilirubin levels greater than or equal to 2 times the upper limit of normal or alkaline phosphatase levels greater than or equal to 3 times the upper limit of normal. - Use of cannabis or any THC or CBD-containing product within 3 months of Screening Visit or during the study (aside from ZYN002). - Patient has a positive drug screen, including ethanol, cocaine, THC, barbiturates, amphetamines (unless prescribed), benzodiazepines (except midazolam or comparable administered for blood draws and ECG collection), and opiates. - Patient is using the following AEDs (medications for the treatment of seizures and/ or epilepsy): clobazam, phenobarbital, ethosuximide, felbamate, carbamazepine, phenytoin, or vigabatrin. - Patient is using a strong inhibitor/inducer of CYP3A4 or sensitive substrate of CYP3A4 including but not limited to the following medications: midazolam (except single doses administered for the purposes of obtaining blood samples and ECG's), oral ketoconazole, fluconazole, nefazadone, rifampin, alfentanil, alfuzosin, amiodarone, cyclosporine, dasatinib, docetaxol, eplerenone, ergotamine, everolimus, fentanyl, halofantrine, irinotecan, lapatinib, levomethadyl, lumefantrine, nilotinib, pimozide, quinidine, ranolazine, sirolimus, tacrolimus, temsirolimus, toremifene, tretinioin, vincristine, vinorelbine, St. John's Wort, and grapefruit Juice/products. - Patients may not be taking any benzodiazepines (except single doses administered for the purposes of obtaining blood samples and ECGs) at screening or throughout the study. - Patient is expected to initiate or change pharmacologic or non-pharmacologic interventions during the course of the study. - Patient has an advanced, severe, or unstable disease that may interfere with the study outcome evaluations. - Patient has acute or progressive neurological disease, psychosis, schizophrenia or any other psychiatric disorder or severe mental abnormalities (other than FXS) that are likely to require changes in drug therapy or interfere with the study objectives or ability to adhere to protocol requirements. - Patient has a positive result for the presence of HBsAg, HCV, or HIV antibodies. - Patient has known history of cardiovascular disease, advanced arteriosclerosis, structural cardiac abnormality, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease, cardiac conduction problems, exercise-related cardiac events including syncope and pre-syncope, risk factors for Torsades de pointes (TdP) (e.g., heart failure, hypokalemia, family history of Long QT Syndrome), or other serious cardiac problems. - Any clinically significant condition or abnormal findings at the Screening Visit that would, in the opinion of the Investigator, preclude study participation or interfere with the evaluation of the study medication. - Any skin disease or condition including eczema, psoriasis, melanoma, acne, contact dermatitis, scarring, imperfections, lesions, tattoos, or discoloration that may affect treatment application, application site assessments or absorption of the trial drug. - History of treatment for, or evidence of, drug abuse within the past year. - Previous participation in a ZYN002 study (with the exception of patients who were screen failures in Study ZYN2-CL-016 and did not enter Study ZYN2-CL-017). - Patient responds "yes" to Question 4 or 5 on the C-SSRS (Children) during Screening or at any time on study.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
ZYN002 - transdermal gel
Pharmaceutically manufactured cannabidiol formulated as a clear gel that can be applied to the skin (transdermal delivery)
Placebo
Placebo formulated as a clear gel that can be applied to the skin (transdermal delivery) Other Names: Placebo Comparator Matching Placebo

Locations

Country Name City State
Australia Flinders Medical Centre Bedford Park South Australia
Australia Lady Cilento Children's Hospital - South Brisbane Brisbane Queensland
Australia Genetics Clinics Australia Melbourne Victoria
Australia Westmead Children's Hospital Sydney New South Wales
Ireland Wellcome HRB Clinical Research Facility Dublin
United Kingdom University of Edinburgh Edinburgh
United Kingdom Leicester Clinical Research Leicester
United Kingdom King's College London
United Kingdom Manchester University NHS Foundation Trust Manchester
United States Rare Disease Research Atlanta Georgia
United States Kennedy Krieger Institute Baltimore Maryland
United States Boston Children's Hospital Boston Massachusetts
United States Rush University Medical Center Chicago Illinois
United States Science 37 Culver City California
United States Greenwood Genetic Center Greenville South Carolina
United States Penn State Hershey Medical Center Hershey Pennsylvania
United States University of Mississippi Jackson Mississippi
United States University of Miami Miami Florida
United States University of Minnesota Fragile X Clinic (Voyager Clinic) Minneapolis Minnesota
United States The Fragile X Spectrum Disorder Clinic at Icahn School of Medicine at Mount Sinai, Division of Medical Genetics New York New York
United States Thompson Autism Center CHOC Orange California
United States UC Davis Health System, MIND Institute Sacramento California
United States Primary Children's Hospital Salt Lake City Utah
United States Central States Research Tulsa Oklahoma
United States Children's National Medical center Washington District of Columbia

Sponsors (1)

Lead Sponsor Collaborator
Zynerba Pharmaceuticals, Inc.

Countries where clinical trial is conducted

United States,  Australia,  Ireland,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Aberrant Behavior Checklist-Community Fragile X Factor Structure (ABC-C FXS) Pre-specified Subscale 1 score in patients with complete methylation (100%) of the FMR1 gene. The ABC-C FXS is a standard parent/caregiver reported behavioral outcome measure for use in developmental disability clinical trials Change from Baseline to Week 18
Secondary Aberrant Behavior Checklist-Community, Fragile X Factor Structure (ABC-C FXS) Pre-specified Subscale 2 in patients with complete methylation (100%) of the FMR1 gene. The ABC-C FXS is a standard parent/caregiver reported behavioral outcome measure for use in developmental disability clinical trials Change from Baseline to Week 18
Secondary Change on the Caregiver Global Impression of Change (CaGI-C) for Pre-specified parameter among patients with complete methylation (100%) of the FMR1 gene. The CaGI-C global impression of change is a 7-point Likert scale designed to measure behavioral symptomatic change at a specific time compared to baseline. Change from Baseline to Week 18
Secondary Clinical Global Impression- Improvement (CGI-I) scale among patients with complete methylation (100%) of the FMR1 gene. The CGI-I global improvement item is a 7-point Likert scale to rate the behavioral change in a child at a specified time compared to baseline. Change from Baseline to Week 18
Secondary Change in ABC-C FXS pre-specified Subscale 1 among all randomized patients (complete and partial methylation of the FMR1 gene). The ABC-C FXS is a standard parent/caregiver reported behavioral outcome measure for use in developmental disability clinical trials Change from Baseline to Week 18
Secondary Number of patients with adverse events Collection of adverse events Day 1, Week 2, Week 4, Week 6, Week 10, Week 14, Week 18 and through 4-week post-dose telephone follow-up
Secondary Number of participants with abnormal physical and neurological exams Physical and neurological exams Screening, Day 1 and Week 18
Secondary Number of participants with abnormal clinical laboratory results Laboratory tests and urinalysis Screening, Week 10 and Week 18
Secondary Number of participants with abnormal vital sign results Vital sign measurements (blood pressure, heart rate, respiratory rate and temperature) Screening, Day 1, Week 2 and Week 18
Secondary Number of participants with abnormal ECG 12-lead ECG Screening and Week 18
Secondary Withdrawal characteristics of ZYN002 using the Penn Physician Withdrawal Checklist Penn Physician Withdrawal Checklist Week 18 and 4-week post last dose
Secondary Skin tolerability as assessed using daily skin diary Daily skin irritation diary Daily from Day 1 through Week 18
See also
  Status Clinical Trial Phase
Recruiting NCT05418049 - Evaluating the Neurophysiologic and Clinical Effects of Single Dose Drug Challenge Phase 2
Enrolling by invitation NCT01364818 - Brain Connectivity in Neurodevelopmental Disorders in Response to Treatment N/A
Completed NCT00965432 - A Single-Dose Study in Normal Volunteers to Assess the Safety, Tolerability and Pharmacokinetics of STX107 Phase 1
Completed NCT01120626 - Randomized Controlled Study of Donepezil in Fragile X Syndrome Phase 2
Completed NCT01204151 - Teaching Math Skills to Individuals With Fragile X Syndrome N/A
Active, not recruiting NCT00334971 - Aromatase Activity and Ovarian Growth Factors in African-American Versus Caucasian Women N/A
Enrolling by invitation NCT06139172 - Promoting Prosocial Behavior in Syndromic Intellectual and Developmental Disabilities N/A
Active, not recruiting NCT04698551 - NIPD on cffDNA for Triplet Repeat Diseases
Completed NCT03722290 - Metformin in Children and Adults With Fragile X Syndrome Phase 2
Completed NCT05030129 - Single Blind Study of Ergoloid Mesylates, 5-HTP and the Combination in Adult Males With Fragile X Syndrome Phase 2
Recruiting NCT05957549 - Tracking Early Emergence of Sound Perception Impairments in FXS With Multimodal fNIRS/EEG N/A
Recruiting NCT04141163 - Metformin in Patients With Fragile X Phase 1/Phase 2
Not yet recruiting NCT06081348 - Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders Phase 2
Completed NCT00858689 - Add-on Pilot Trial of Minocycline to Treat Fragile X Syndrome N/A
Enrolling by invitation NCT03655223 - Early Check: Expanded Screening in Newborns
Enrolling by invitation NCT03802799 - Open Label Extension to Assess the Long-Term Safety and Tolerability of ZYN002 in Children and Adolescents With FXS Phase 2/Phase 3
Recruiting NCT05295277 - Validation of Optical Genome Mapping for the Identification of Constitutional Genomic Variants in a Postnatal Cohort
Enrolling by invitation NCT03836300 - Parent and Infant Inter(X)Action Intervention (PIXI) N/A
Completed NCT01725152 - Ganaxolone Treatment in Children With Fragile X Syndrome Phase 2
Terminated NCT01555333 - An Open Label Extension Study in Subjects With Fragile X Syndrome Phase 3